Scarica l'app Stockscreener
10.92
10.27%
-1.25
Dopo l'orario di chiusura:
10.75
-0.17
-1.56%
Precedente Chiudi:
$12.17
Aprire:
$12.11
Volume 24 ore:
968.61K
Relative Volume:
1.61
Capitalizzazione di mercato:
$551.62M
Reddito:
$89.04M
Utile/perdita netta:
$-241.08M
Rapporto P/E:
-2.076
EPS:
-5.26
Flusso di cassa netto:
$-194.72M
1 W Prestazione:
+4.70%
1M Prestazione:
+14.11%
6M Prestazione:
+101.85%
1 anno Prestazione:
+17.55%
Intervallo 1D:
$10.91
$12.14
Intervallo di 1 settimana:
$10.24
$12.84
Portata 52W:
$5.035
$12.84
Regenxbio Inc Stock (RGNX) Company Profile
Nome
Regenxbio Inc
Settore
Industria
Telefono
240-552-8181
Indirizzo
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Confronta RGNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
10.92 | 614.76M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-11 | Downgrade | Goldman | Buy → Neutral |
| 2025-02-07 | Ripresa | Raymond James | Outperform |
| 2024-11-15 | Ripresa | Morgan Stanley | Overweight |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-06-07 | Iniziato | Goldman | Buy |
| 2024-03-11 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-08 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Ripresa | Raymond James | Outperform |
| 2023-11-01 | Iniziato | Stifel | Buy |
| 2023-06-02 | Iniziato | Robert W. Baird | Outperform |
| 2022-06-23 | Iniziato | Berenberg | Buy |
| 2021-12-15 | Iniziato | Wedbush | Neutral |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-01-06 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-06-25 | Ripresa | BofA/Merrill | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-14 | Ripresa | Raymond James | Outperform |
| 2019-06-05 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-25 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Reiterato | Chardan Capital Markets | Buy |
| 2018-11-08 | Reiterato | BofA/Merrill | Neutral |
| 2018-08-08 | Reiterato | Chardan Capital Markets | Buy |
| 2018-07-23 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Reiterato | Chardan Capital Markets | Buy |
| 2018-05-09 | Reiterato | Barclays | Overweight |
| 2018-04-09 | Reiterato | Chardan Capital Markets | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Iniziato | Mizuho | Neutral |
| 2017-11-09 | Ripresa | Morgan Stanley | Overweight |
Mostra tutto
Regenxbio Inc Borsa (RGNX) Ultime notizie
Price momentum metrics for REGENXBIO Inc. explained2025 Performance Recap & Technical Pattern Alert System - newser.com
Market reaction to REGENXBIO Inc.’s recent newsQuarterly Trade Report & Expert Verified Stock Movement Alerts - newser.com
What does recent volatility data suggest for REGENXBIO Inc.Trade Analysis Report & Consistent Profit Focused Trading Strategies - newser.com
REGENXBIO (NASDAQ:RGNX) CEO Curran Simpson Sells 20,811 Shares - MarketBeat
Insider Sell: Curran Simpson Sells Shares of Regenxbio Inc (RGNX) - GuruFocus
Regenxbio CEO Simpson Curran sells $262,634 in stock - Investing.com
Chart based analysis of REGENXBIO Inc. trendsWeekly Trade Summary & Safe Entry Momentum Tips - newser.com
REGENXBIO (NASDAQ:RGNX) Reaches New 12-Month HighTime to Buy? - MarketBeat
REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting - Eastern Progress
Why REGENXBIO Inc. is moving todayWeekly Profit Report & Long-Term Safe Return Strategies - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for REGENXBIO (NASDAQ:RGNX) - MarketBeat
Is REGENXBIO Inc. trending in predictive chart modelsJuly 2025 Big Picture & Smart Allocation Stock Tips - newser.com
How to build a dashboard for REGENXBIO Inc. stockEarnings Summary Report & Free Real-Time Market Sentiment Alerts - newser.com
How cyclical is REGENXBIO Inc. (RB0) stock compared to rivalsJuly 2025 Market Mood & Safe Entry Trade Reports - newser.com
REGENXBIO, Inc. Hits New 52-Week High at $12.30 - Markets Mojo
2-Year Results: REGENXBIO Presents ALTITUDE Phase II Data for Diabetic Retinopathy Oct 17 - Stock Titan
REGENXBIO Inc. (NASDAQ:RGNX) Held Back By Insufficient Growth Even After Shares Climb 29% - simplywall.st
Using data filters to optimize entry into REGENXBIO Inc.Insider Selling & Weekly Chart Analysis and Guides - newser.com
Is REGENXBIO Inc. stock positioned for digital transformationTrade Risk Report & Reliable Entry Point Alerts - newser.com
Is REGENXBIO Inc. (RB0) stock a top hedge fund pickTrade Risk Assessment & Free High Return Stock Watch Alerts - newser.com
REGENXBIO (NASDAQ:RGNX) Trading 9.1% HigherShould You Buy? - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
REGENXBIO's (RGNX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
HC Wainwright & Co. Reiterates REGENXBIO (RGNX) Buy Recommendation - Nasdaq
Regenxbio stock maintains Buy rating at H.C. Wainwright on gene therapy potential - Investing.com
HC Wainwright & Co. Reiterates Buy Rating for RGNX with $34 Targ - GuruFocus
Viral Vector Gene Therapy Market Size Expects to Reach USD 38.39 Billion by 2034 - GlobeNewswire Inc.
Regenxbio Inc. Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet Amd - MarketScreener
REGENXBIO completes enrollment in wet AMD gene therapy trials - Investing.com
RGNX Completes Enrollment for Key Macular Degeneration Studies - GuruFocus
REGENXBIO completes enrollment in wet AMD gene therapy trials By Investing.com - Investing.com Nigeria
Regenxbio announces completion of enrollment in pivotal trials of subretinal surabgene lomparvovec for wet AMD - MarketScreener
Regenxbio announces completion of enrollment in pivotal trials of subretinal surabgene lomparvovec for WET AMD - TradingView
1,200+ Enrolled: REGENXBIO Completes Largest Gene Therapy Wet AMD Program; Topline Q4 2026 - Stock Titan
What indicators show strength in REGENXBIO Inc.2025 Trading Recap & Low Risk High Win Rate Picks - newser.com
Combining price and volume data for REGENXBIO Inc.2025 Fundamental Recap & Expert Curated Trade Setup Alerts - newser.com
Will REGENXBIO Inc. stock gain from lower inflation2025 Performance Recap & Technical Pattern Based Signals - newser.com
Is REGENXBIO (NASDAQ:RGNX) A Risky Investment? - simplywall.st
Is REGENXBIO Inc a good long term investmentTechnology Stock Trends & Superior Capital Investment - earlytimes.in
Batten Disease Pipeline 2025: Innovative Clinical Developments by 10+ Global Leaders – DelveInsight | Featuring Polaryx Therapeutics, Neurogene, Theranexus, M6P Therapeutics, Regenxbio - The Globe and Mail
REGENXBIO Inc. $RGNX Shares Sold by Voya Investment Management LLC - MarketBeat
Regenxbio (RGNX) CEO Simpson Curran sells $76k in shares By Investing.com - Investing.com Nigeria
Insider Sell Alert: Curran Simpson Sells Shares of Regenxbio Inc (RGNX) - GuruFocus
Curran Simpson Sells 7,624 Shares of REGENXBIO (NASDAQ:RGNX) Stock - MarketBeat
Regenxbio (RGNX) CEO Simpson Curran sells $76k in shares - Investing.com
Regenxbio Inc Azioni (RGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):